Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 501–600 of 810
The broken Alzheimer’s disease genome
Roque, C. G., Phatnani, H. P., & Hengst, U. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100555 · Cited by 15
Fruitful research: drug target discovery for neurodegenerative diseases in Drosophila
Konsolaki, M. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.849691 · Cited by 16
“Numerous studies have examined the role of ApoE in the development of AD, and it is generally believed that ApoE binds Ab and is a regulator of Ab trafficking in the brain [30].”
BackgroundAPP -Induced Patterned Neurodegeneration Is Exacerbated by APOE4 in Caenorhabditis elegans
Sae-Lee, W., Scott, L. L., Brose, L., Encarnacion, A. J., Shi, T., Kore, P., Oyibo, L. O., Ye, C., Rozmiarek, S. K., & Pierce-Shimomura, J. T. (2020) · G3 Genes Genomes Genetics · doi:10.1534/g3.120.401486 · Cited by 13
Differences in Recycling of Apolipoprotein E3 and E4—LDL Receptor Complexes—A Mechanistic Hypothesis
Kim, M., & Bezprozvanny, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095030 · Cited by 11
“These domains are involved in the association with extracellular ligands [2,6,32].”
BackgroundFunctional insight into LOAD-associated microglial response genes
Jonas, L. A., Jain, T., & Li, Y. (2022) · Open Biology · doi:10.1098/rsob.210280 · Cited by 16
“Impaired binding of Aβ-apoE and TREM2 may potentially affect both microglial recognition of amyloid pathogens and subsequent clearance of plaques [94,95].”
BackgroundRNA-Seq Mouse Brain Regions Expression Data Analysis: Focus on ApoE Functional Network
Babenko, V. N., Смагин, Д. А., & Kudryavtseva, N. N. (2017) · Berichte aus der medizinischen Informatik und Bioinformatik/Journal of integrative bioinformatics · doi:10.1515/jib-2017-0024 · Cited by 13
“APOE is featured as a major apolipoprotein that mediates the cholesterol and lipid metabolism upon binding the (very) low-density lipoprotein receptors, including low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDR), and some of the low density lipoprotein receptor-related protein (LRP…”
BackgroundHayashi, H., Mori, M., Harashima, M., Hashizume, T., Furiya, M., Mukaigaito, C., Takemura, E., Yamada, M., Mise, K., Yuan, B., et al. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.13.23 · Cited by 15
Chiba‐Falek, O., & Lutz, M. W. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1286227 · Cited by 14
Trusca, V. G., Fuior, E. V., Kardassis, D., Simionescu, M., & Gafencu, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061471 · Cited by 14
“It functions as a ligand in receptor-mediated endocytosis of lipoprotein particles, mediating lipid transfer between the circulating lipoproteins and tissues through its functional domains: the lipid-binding region and the receptor-binding region [3,4].”
BackgroundHomeostasis of Lipid Metabolism in Disorders of the Brain
Johnson, J. L., & Johnson, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819641-0.00146-8 · Cited by 14
Yang, X., Yao, K., Zhang, M., Zhang, W., & Zu, H. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111321 · Cited by 12
“Collectively, gene polymorphisms of LDLR family influence the uptake and trafficking of apoE-mediated cellular cholesterol, which could be associated with AD pathology (Carter et al., 2007; Holtzman et al., 2012; Go et al., 2012; Lane-Donovan ad Herz, 2017).”
InfluentialSuhrie, K. R., Hammers, D. B., Porter, S. M., Dixon, A. M., King, J. B., Anderson, J. S., Duff, K. M., & Hoffman, J. M. (2021) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803395.2021.2023476 · Cited by 13
“APOE ε4 is a genetic risk factor that has been extensively implicated in AD (Holtzman et al., 2012; Mayeux et al., 1993; Petersen et al., 1995).”
BackgroundApplications of Nanoparticles in Alzheimer’s Disease
Liu, Y., & Shen, Y. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230098 · Cited by 15
“Multiple ligands can bind to receptors, and they have been employed for drug delivery targets [34].”
Random Forest and Gene Networks for Association of SNPs to Alzheimer’s Disease
de Araújo, G. S., Souza, M. R. B., de Oliveira, J. R. M., & Costa, I. G. (2013) · Lecture notes in computer science · doi:10.1007/978-3-319-02624-4_10 · Cited by 13
Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier
Wong, K. H., Riaz, M. K., Xie, Y., Zhang, X., Liu, Q., Chen, H., Bian, Z., Chen, X., Lü, A., & Yang, Z. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20106 · Cited by 13
Map kinase and PKC signaling pathways modulate NGF-mediated apoE transcription
Strachan-Whaley, M. R., Reilly, K., Dobson, J., & Kalisch, B. E. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.03.032 · Cited by 13
Developing Trojan horses to induce, diagnose and suppress Alzheimer’s pathology
Aziz, A. A., & Amtul, Z. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104471 · Cited by 15
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin
Graykowski, D. R., Kasparian, K., Caniglia, J. L., Gritsaeva, Y., & Cudaback, E. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577315 · Cited by 12
Lizama, B. N., Keeling, E., Cho, E.-A., Malagise, E. M., Knezovich, N., Waybright, L., Watto, E., Look, G. C., Caro, V. D., Caggiano, A. O., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87921-9 · Cited by 11
Brain health registry GenePool study: A novel approach to online genetics research
Fockler, J., Kwang, W., Ashford, M. T., Flenniken, D., Hwang, J. C., Truran, D., Mackin, R. S., Jin, C., O'Hara, R. M., Hallmayer, J. F., et al. (2021) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12118 · Cited by 13
Cakir, Z., Lord, S. J., Zhou, Y. M., Jang, G. Μ., Polacco, B. J., Eckhardt, M., Jimenez‐Morales, D., Newton, B. W., Orr, A. L., Johnson, J. R., et al. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100541 · Cited by 13
Yazdi, M. K., Alavi, M. S., & Roohbakhsh, A. (2024) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13981 · Cited by 12
Scheinman, S. B., Zaldua, S., Dada, A., Krochmaliuk, K., Dye, K., Marottoli, F. M., Thatcher, G. R. J., & Tai, L. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.628403 · Cited by 11
Diaz, J. R., Martá-Ariza, M., Khodadadi‐Jamayran, A., Heguy, A., Tsirigos, A., Pankiewicz, J. E., Sullivan, P. M., & Sadowski, M. J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.845291 · Cited by 12
NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
Painuli, S., Semwal, P., Zam, W., Taheri, Y., Ezzat, S. M., Zuo, P., Li, L., Kumar, D., Sharifi‐Rad, J., & Martins, N. A. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220428112541 · Cited by 12
López‐Font, I., Lennol, M. P., Iborra‐Lázaro, G., Zetterberg, H., Blennow, K., & Sáez‐Valero, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147522 · Cited by 12
“The apoE protein is secreted mainly by glial cells in the central nervous system [6], and it participates in cholesterol and lipid transport in the brain [7,8], amongst other physiological functions, including signaling through receptor interactions [6].”
BackgroundKothari, S., Bala, N., Patel, A., Donovan, A., & Narayanaswami, V. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2021.183618 · Cited by 11
“While the CT domain plays a major role in the initial step of cholesterol efflux, the NT domain bearing the LDLr binding sites is responsible for cellular uptake of the cholesterol-laden lipoprotein via the lipoprotein receptor family of proteins [72,73].”
BackgroundEffects of DHA (omega-3 fatty acid) and estradiol on amyloid β-peptide regulation in the brain
Majou, D., & Dermenghem, A.-L. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148681 · Cited by 11
Patil, S. P., Kuehn, B. R., McCullough, C., Bates, D., Hazim, H., Diallo, M., & Francois, N. (2025) · Molecules · doi:10.3390/molecules30040940 · Cited by 10
Mahanta, A. K., Chaulagain, B., Gothwal, A., & Singh, J. (2025) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c00465 · Cited by 13
What Is the Role of Microglial Metabolism in Inflammation and Neurodegeneration?
Benarroch, E. E. (2022) · Neurology · doi:10.1212/wnl.0000000000200920 · Cited by 11
“After uptake from ApoE lipoprotein particles, cholesterol exits the microglia via a mechanism mediated by the ATP-binding cassette transporters ABCA1 and ABCG1 and then becomes incorporated into ApoE containing high-density lipoprotein particles.(97,104) The major mechanism for elimination of cholesterol from the brai…”
BackgroundStructural basis of Semliki Forest virus entry using the very-low-density lipoprotein receptor
Li, Y., Zhao, Z.-N., Liu, S., Wang, H.-C., Sun, J.-Q., Chai, Y., Zhou, J.-Y., Wang, Y.-N., Shi, Y., Song, H., et al. (2023) · hLife · doi:10.1016/j.hlife.2023.11.001 · Cited by 8
“All three receptors, VLDLR, ApoER2, and LDLR, bind apolipoprotein E [21].”
Apolipoprotein E receptor pathways in Alzheimer disease
Schmidt, V., Carlo, A.-S., & Willnow, T. E. (2014) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1262 · Cited by 11
Neuronal ApoE Regulates the Cell-to-Cell Transmission of α-Synuclein
Kang, S., Kim, S., Noh, H. R., Kim, B. J., Kim, J.-B., Jin, U., Park, S. A., & Park, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158311 · Cited by 11
Building in vitro models of the brain to understand the role ofAPOEin Alzheimer’s disease
Pinals, R. L., & Tsai, L. (2022) · Life Science Alliance · doi:10.26508/lsa.202201542 · Cited by 10
“Expression of APOE ε4 is reported to cause increased Aß aggregation within and impaired clearance out of the brain, in addition to other processes including synaptic dysfunction and neuroinflammation (Kim et al, 2009; Castellano et al, 2011; Holtzman et al, 2012; Knopman et al, 2021).”
BackgroundInfluentialYoung, J. E., & Goldstein, L. S. B. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2655-9_6 · Cited by 10
Wagner, W., Reuter, A., Hüller, P., Löwer, J., & Weßler, S. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-38 · Cited by 10
“strongest genetic risk factors in Alzheimer disease [15].”
BackgroundDysregulation of neuroproteasomes by ApoE isoforms drives endogenous Tau aggregationPreprint
Paradise, V., Sabu, M., Bafia, J., Sharif, N., Nguyen, C., Konrad-Vicario, K., Mukim, R. D., Wang, X., Corjuc, B., Fu, J. M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.29.518293 · Cited by 11
Self-citationRodríguez-López, A., Esteban, D., Domínguez‐Romero, A. N., & Gevorkian, G. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115189 · Cited by 9
APOE4 drives widespread changes to the hepatic proteome and alters metabolic function
Lysaker, C. R., Johnson, C. N., Csikós, V., Franczak, E., Tetlow, A. L., Benson, M. N., Thyfault, J. P., Geiger, P. C., Morris, J. K., & Wilkins, H. (2026) · iScience · doi:10.1016/j.isci.2026.115035 · Cited by 10
Chen, X. R., Shao, Y., Sadowski, M. J., & Initiative, O. B. O. T. A. D. N. (2023) · Genes · doi:10.3390/genes14040917 · Cited by 11
“Examples of ε4–related mechanisms that are detrimental to cognitive performance during aging and AD include hyperexcitability of hippocampal networks [38], age-related loss of hippocampal interneurons [39,40], and dysfunctional endosomal trafficking, resulting in reduced surface expression of NMDAR subunits [41,42].”
BackgroundLipoprotein metabolism mediates hematopoietic stem cell responses under acute anemic conditions
Saito, K., van der Garde, M., Umemoto, T., Miharada, N., Sjöberg, J., Sigurðsson, V., Shirozu, H., Kamei, S., Radulović, V., Suzuki, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52509-w · Cited by 10
Epigenomics of Alzheimer’s Disease
Bennett, D. A., Yu, L., Yang, J., Klein, H., & Jager, P. L. D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800802-7.00009-5 · Cited by 11
Lipid Dyshomeostasis and Inherited Cerebellar Ataxia
Zhao, J., Zhang, H., Fan, X., Yu, X., & Huai, J. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02826-2 · Cited by 9
The Impact of the Apolipoprotein E Genotype on Cardiovascular Disease and Cognitive Disorders
McMaster, M. W., Shah, A., Kangarlu, J., Cheikhali, R., Frishman, W. H., & Aronow, W. S. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000703 · Cited by 11
The Genetic Basis of Alzheimer's Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00034-2 · Cited by 9
Insulin resistance in patients with Alzheimer’s dementia: A controlled study from India
Thankappan, S., Sen, S., Subramanian, S., Sinha, P., Purushottam, M., & Bharath, S. (2018) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2018.10.026 · Cited by 10
Elevated Membrane Cholesterol Disrupts Lysosomal Degradation to Induce β-Amyloid Accumulation
Takeuchi, S., Ueda, N., Suzuki, K., Shimozawa, N., Yasutomi, Y., & Kimura, N. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.10.011 · Cited by 10
Marshall, J. P. S., Huynh, K., Lancaster, G. I., Ng, J., Collins, J. M., Pernes, G., Liang, A., Featherby, T. J., Mellet, N. A., Drew, B. G., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108800 · Cited by 8
“41,42 46 Little is known about how alterations to APP and tau in pre-clinical models alter lipid handling, particularly at the molecular lipid specieslevel.”
BackgroundLipid-bound ApoE3 self-assemble into elliptical disc-shaped particles
Larsen, A. H., Johansen, N. T., Gajhede, M., Arleth, L., & Midtgaard, S. R. (2020) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2020.183495 · Cited by 9
Evaluating the effect of kidney function on brain volumes and dementia risk in the UK Biobank
Huang, X., Yuan, S., Ling, Y., Cheng, H., Tan, S., Xu, A., & Lyu, J. (2023) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2023.105157 · Cited by 9
Safieh, M., Liraz, O., Ovadia, M., & Michaelson, D. M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230514 · Cited by 9
“These receptors have an NPXY motif at their cytoplasmic domain and have been implicated in endocytosis [37, 39, 40], which results in the trafficking of the receptors between the cell surface and intracellular compartments [41, 42].”
BackgroundAPOE4 drives maladaptive heterogeneity and immunometabolic responses of astrocytes
Lee, S., Williams, H. C., Gorman, A. A., Devanney, N. A., Harrison, D. A., Walsh, A. E., Goulding, D. S., Tuck, T., Schwartz, J. L., Zajac, D. J., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03698-2 · Cited by 12
“Prior work has demonstrated that APOE4 astrocytes show enhanced interactions with amyloid-β aggregation (Holtzman et al., 2012) and that selective removal of astrocytic APOE4 is sufficient to reduce tau-mediated neurodegeneration and synaptic phagocytosis (Wang et al., 2021; Mahan et al., 2022).”
Stachowicz, A., Olszanecki, R., Suski, M., Głombik, K., Basta‐Kaim, A., Adamek, D., & Korbut, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020435 · Cited by 8
“In the brain it is predominantly synthetized by astrocytes and microglia, and involved in cholesterol transport as well as in the development and regeneration of the central nervous system (CNS) [19].”
BackgroundExtra-Hippocampal Learning Deficits in Young Apolipoprotein E4 Mice and Their Synaptic Underpinning
Har-Paz, I., Roisman, N., Michaelson, D. M., & Moran, A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190564 · Cited by 8
“Several genetic risk factors are correlated with late-onset Alzheimer’s disease (AD), with the (cid:2) 4 allele of apolipoprotein E (apoE4) being the most prevalent one [1, 2].”
The Janus-like Association between Proton Pump Inhibitors and Dementia
Papazoglou, A., Arshaad, M. I., Henseler, C., Daubner, J., Broich, K., Haenisch, B., & Weiergräber, M. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210929144740 · Cited by 8
Gui, Y., Duan, Z., Qiu, X., Tang, W., Gober, H.-J., Li, D., & Wang, L. (2016) · BioScience Trends · doi:10.5582/bst.2016.01006 · Cited by 9
Pleiotropic Effect of Human ApoE4 on Cerebral Ceramide and Saturated Fatty Acid Levels
den Hoedt, S., Janssen, C. I. F., Astarita, G., Piomelli, D., Leijten, F. P. J., Crivelli, S. M., Verhoeven, A. J. M., de Vries, H. E., Walter, J., Martínez‐Martínez, P., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160739 · Cited by 8
“Similar to its role in the circulation, ApoE is thought to play a role in lipid trafficking in the brain [3].”
Šutovský, S., Petrovič, R., Fischerová, M., Haverlíková, V., Ukropcová, B., Ukropec, J., & Turčáni, P. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200321 · Cited by 10
“APOE is highly expressed in the brain, primarily in the astrocytes, but its function is only partially understood [14].”
Arnsten, A., Perone, I., Wang, M., Yang, S.-T., Uchendu, S. N., Bolat, D., & Datta, D. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1610350 · Cited by 6
“APOE is a key protein in the brain, responsible for lipid and cholesterol metabolism (Holtzman et al., 2012; Raulin et al., 2022).”
Lee, H., Hossain, M. K., Lee, H.-Y., Kumar, V., Shin, S. J., Kim, B., Park, H. H., Son, J. G., Moon, M., & Kim, H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118527 · Cited by 8
Astrocytes and Memory: Implications for the Treatment of Memory-related Disorders
Wang, J., Cheng, P., Qu, Y., & Zhu, G. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240128102039 · Cited by 8
“APOE4 is a known risk gene for AD [141]; a previous study reported that astrocytes are the major cell type that produces the most APOE [142].”
BackgroundXu, Y., Zhang, J., & Li, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1328334 · Cited by 8
Vermeren, M., Zhang, Q., Smethurst, E. A., Segonds-Pichon, A., Schrewe, H., & Wakelam, M. J. O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162814 · Cited by 7
Plasma Levels of Amyloid-β Peptides and Tau Protein in Mexican Patients with Alzheimer’s Disease
Castillo-Mendieta, T., Arana-Lechuga, Y., Campos‐Peña, V., Sosa, A. L., Orozco-Suárez, S. A., Pinto‐Almazán, R., Segura-Uribe, J. J., de Tagle, A. J. R.-S., Ruiz-Sánchez, E., & Guerra‐Araiza, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-200912 · Cited by 8
“4 allele, a strong genetic risk factor for AD, is associated with earlier and higher deposition of A (cid:2) [14].”
Bidirectional Control between Cholesterol Shuttle and Purine Signal at the Central Nervous System
Passarella, D., Ronci, M., Liberto, V. D., Zuccarini, M., Mudò, G., Porcile, C., Frinchi, M., Iorio, P. D., Ulrich, H., & Russo, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158683 · Cited by 9
“Together with LRP1, LDLR represent the primary metabolic receptors for ApoE/lipoprotein in the brain and are linked to beta amyloid (Aβ) clearance, avoiding the cerebral deposition of this peptide.”
BackgroundInfluentialSingle cell molecular alterations reveal target cells and pathways of conditioned fear memory
Shen, M., Shang, M., Tian, R.-F., Hu, Y., Han, Q., Hu, J., An, G., Wang, B., Cao, Z., Lin, X., et al. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148309 · Cited by 8
Zhang, X., Gao, R., Yang, L., Zhu, Y., Zhang, T., Shen, X., Gu, W., Yang, L., & Peng, S. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.287 · Cited by 12
Chen, X., Liang, H., Soliman, M. L., & Geiger, J. D. (2014) · Journal of Parkinson’s Disease and Alzheimer’s Disease · doi:10.13188/2376-922x.1000002 · Cited by 10
“To accommodate the neuronal need for cholesterol, a large number of receptors for cholesterol uptake, including low-density lipoprotein receptor (LDLR), very low-density lipoprotein receptor (VLDLR), LDLR related protein-1 (LRP-1), apoE receptor, and sorting protein-related receptor containing LDLR class A repeats (so…”
Barati, M., & Ebrahimi, M. (2016) · Gene Cell and Tissue · doi:10.17795/gct-38415 · Cited by 7
“Gradually, physical performance is lost and it causes death (8).”
BackgroundAn Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer’s Disease
Menta, B. W., & Swerdlow, R. H. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2603-y · Cited by 7
Sarlak, Z., Moazzami, M., Hosseini, S. R. A., & Gharakhanlou, R. (2019) · PubMed Central · doi:10.22038/ijbms.2018.32911.7860 · Cited by 11
“It is a chaperone for Aβ; it affects the deposition and clearance of Aβ (15, 16).”
BackgroundAlzheimers's disease: Epidemiological characteristics and its prevention
Grujičić, J., & Nikolić, A. (2021) · Zdravstvena zastita · doi:10.5937/zdravzast50-32931 · Cited by 8
APOE Is Associated With Serum Tau Following Uncomplicated Mild Traumatic Brain Injury
Lippa, S. M., Lange, R. T., Dalgard, C. L., Soltis, A. R., Guedes, V. A., Brickell, T. A., French, L. M., & Gill, J. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.816625 · Cited by 7
APOE: A Risk Factor for Multiple Disorders
Myers, A., & Nemeroff, C. B. (2012) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e318259b9a5 · Cited by 8
Association between dementia and vascular disease-associated polymorphisms in a Tunisian population
Hamdouni, H., Achour, O., Salma, N., Rejeb, J., Mariam, A., Mariem, M., Mariem, N., Rejeb, N. B., Asma, O., Sana, B. A., et al. (2017) · International Journal of Neuroscience · doi:10.1080/00207454.2017.1348353 · Cited by 7
“In addition to its involvement in fibrillogenesis, there is evidence that ApoE also serves as a vector in both the transport and clearance of soluble Ab peptides in the brain, with lower activity associated with the ApoE4 variants than ApoE3 and ApoE2 [37].”
BackgroundXie, T., Akbar, S., Stathopoulou, M. G., Oster, T., Masson, C., Yen, F. T., & Visvikis‐Siest, S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.013 · Cited by 8
Ha, E., Kim, M. K., Chun, J., Seo, C., Ahn, Y. M., & Jung, J. (2020) · Biology · doi:10.3390/biology9110363 · Cited by 7
“Individuals with the APOE4 allele show increased susceptibility to late-onset AD [22,23].”
BackgroundGarner, B., & Ooi, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14276 · Cited by 7
APOE genotype and cognitive decline: educational context as a moderator of genetic risk
Walsemann, K. M., Jackson, H. M., Boardman, J. D., & Herd, P. (2025) · The Journals of Gerontology Series B · doi:10.1093/geronb/gbaf110 · Cited by 6
Performance Under Fire: Older Adult Cognitive Risks and Protections Under Heat Strain
Shin, S. H., Walker, S. L., Ji, H., & Lee, H. Y. (2024) · The Gerontologist · doi:10.1093/geront/gnae116 · Cited by 6
“Studies identify genetics as a significant risk factor for late-onset AD and highlight apolipoprotein (APOE) ɛ 4 as the strongest predictor (Holtzman et al., 2012).”
BackgroundLILRB4 as a novel immunotherapeutic target for multiple diseases
Wang, X., Li, L., Liu, D., Jin, Y., Zhao, X., Li, S., Hou, R., Guan, Z., Ma, W., Zheng, J., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116762 · Cited by 6
Vromen, E. M., Lageman, S. B., Gobom, J., van der Kant, R., Dobričić, V., Bertram, L., Streffer, J. R., Lovestone, S., Vos, S. J. B., Tainta, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70738 · Cited by 8
“1,4,5 7 APOE has been implicated in numerous pathways that contribute to AD pathology, including amyloid metabolism and clearance pathways, 8 synaptic plasticity, lipid and glucose metabolism, and neuroinflammation.”
Hsieh, S., Chen, J., Chen, N.-C., Jhang, K.-M., Wang, W., & Yang, Y. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.459 · Cited by 6
“Apolipoprotein E4 (ApoE4) is the most prevalent genetic risk factor of AD [29] with its numerous implications in processes of crosstalk with beta-amyloid (A) and effect on lipid metabolism and inflammation [30-32].”
BackgroundUnderstanding the Intricate Role of Exosomes in Pathogenesis of Alzheimer’s Disease
Chauhan, S., Behl, T., Sehgal, A., Singh, S., Sharma, N., Gupta, S., Albratty, M., Najmi, A., Meraya, A. M., & Alhazmi, H. A. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00621-4 · Cited by 6
“Another gene which also seems to be involved in AD is SORL1 (Eid et al. 2019; Holtzman et al. 2012).”
BackgroundThe Genetic Basis of Alzheimer’s Disease
Hooli, B. V., & Tanzi, R. E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00002-2 · Cited by 6
Enhancement of sAPPα as a Therapeutic Strategy for Alzheimer’s and Other Neurodegenerative Diseases
John, V. (2015) · Alzheimer’s & Neurodegenerative Diseases · doi:10.24966/and-9608/100001 · Cited by 9
Radiation therapy for the treatment of Alzheimer’s disease
Michael, D. B., Wilson, G. D., Hanna, A., Wilson, T., Martinez, A. A., Chinnaiyan, P., Maddens, M. E., & Fontanesi, J. (2019) · Neurology and Neurosurgery · doi:10.15761/nns.1000120 · Cited by 6
“The ε4 allele has been demonstrated as a genetic risk factor for AD, while ε2 confers a protective effect [37].”
Are KIF6 and APOE polymorphisms associated with power and endurance athletes?
Wojciechowicz, B., Laguette, M.-J. N., Sawczuk, M., Humińska‐Lisowska, K., Maciejewska, A., Ficek, K., Michałowska‐Sawczyn, M., Leońska‐Duniec, A., Kaczmarczyk, M., Chycki, J., et al. (2020) · European Journal of Sport Science · doi:10.1080/17461391.2020.1817983 · Cited by 6
Kadey, K. R., Woodard, J. L., Moll, A. C., Nielson, K. A., Smith, J. C., Durgerian, S., & Rao, S. M. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201360 · Cited by 7
“Having one (cid:2) 4 allele triples one’s risk of developing AD and having two (cid:2) 4 alleles is associated with a 12 times greater risk of AD compared to those with no (cid:2) 4 allele [1, 2].”
Advances in the Study of APOE and Innate Immunity in Alzheimer’s Disease
Li, Y., Chang, J., Chen, X., Liu, J., & Zhao, L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230179 · Cited by 6
“On the one hand, APOE4 is closely associated with A (cid:2) in the brain [38].”
Cui, Q., Jeyachandran, A. V., Garcia, G., Qin, C., Zhou, Y., Zhang, M., Wang, C., Sun, G., Liu, W., Zhou, T., et al. (2023) · MedComm · doi:10.1002/mco2.400 · Cited by 7
“3 6 However, how ApoE mediates SARS-CoV-2 cellular entry remains unclear.”
BackgroundLi, H., He, Y., Di, C., Yan, J., & Zhang, H. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.10.029 · Cited by 6
Apolipoprotein E is a pancreatic extracellular factor that maintains mature β-cell gene expression
Mahmoud, A. I., Galdos, F. X., Dinan, K. A., Jedrychowski, M. P., Davis, J. C., Vujić, A., Rachmin, I., Shigley, C., Pancoast, J. R., Lee, S., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204595 · Cited by 7
Amyloid beta accumulation in HIV-1 infected brain: the role of altered cholesterol homeostasis.
Chen, X., Liang, H., & Geiger, J. D. (2014) · PubMed · Cited by 6
Kang, J., Zhang, C., Wang, Y., Peng, J., Berger, B., Perrimon, N., & Shen, J. (2023) · Genetics · doi:10.1093/genetics/iyad202 · Cited by 5
Hackney, J. F., Broatch, J., Dallal, R. A., Brotherson, C., Livingston, S., Sabir, Z. L., Reshi, S. M., Petras, S. R. F., Mallick, S., Applegate, M. T., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00286 · Cited by 5
Gao, Y., Schedin‐Weiss, S., & Tjernberg, L. O. (2024) · Advanced technology in neuroscience . · doi:10.4103/atn.atn-d-24-00014 · Cited by 9
Huang, J., Peng, Y., Wang, X., Gu, X., Yao, Y., Wang, W., He, Z., Ma, Z., Feng, Q., Qi, W., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03016-z · Cited by 5
“After internalization, ligands are released from receptor-ligand complexes, and unli-ganded receptors such as LDLR and LRP1 are recycled to the cell surface to begin the next endocytic cycle [71].”
Unraveling APOE4's Role in Alzheimer's Disease: Pathologies and Therapeutic Strategies
Tripathi, S., Sharma, Y., & Kumar, D. (2024) · Current Protein and Peptide Science · doi:10.2174/0113892037326839241014054430 · Cited by 6
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.